These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28717233)

  • 21. Association between lipoprotein (a) and proprotein convertase substilisin/kexin type 9 in patients with heterozygous familial hypercholesterolemia: A case-control study.
    Sun D; Li S; Zhao X; Wu NQ; Zhu CG; Guo YL; Gao Y; Qing P; Cui CJ; Liu G; Sun J; Dong Q; Li JJ
    Metabolism; 2018 Feb; 79():33-41. PubMed ID: 29129821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two novel mutations in exon 3 and 4 of low density lipoprotein (LDL) receptor gene in patients with heterozygous familial hypercholesterolemia.
    Khan SP; Ghani R; Ahmed KZ; Yaqoob Z
    J Coll Physicians Surg Pak; 2011 Jul; 21(7):403-6. PubMed ID: 21777527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations.
    Viladés Medel D; Leta Petracca R; Carreras Costa F; Cardona Olle M; Barros Membrilla A; Hidalgo Perez JA; Pujadas Olano S; Alomar Serrallach X; Franco Peral M; Pons-Lladó G
    Am J Cardiol; 2013 Apr; 111(7):955-61. PubMed ID: 23340035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statin Therapy and Risk of Diabetes Mellitus in Aging Patients With Heterozygous Familial Hypercholesterolemia or Familial Combined Hyperlipidemia: A 10-Year Follow-Up.
    Skoumas I; Ioakeimidis N; Vlachopoulos C; Chrysohoou C; Michalakeas C; Georgakopoulos C; Katsi V; Panagiotakos D; Tousoulis D
    Angiology; 2018 Mar; 69(3):242-248. PubMed ID: 28681648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
    Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipoprotein(a) in hereditary hypercholesterolemia: Influence of the genetic cause, defective gene and type of mutation.
    Marco-Benedí V; Cenarro A; Laclaustra M; Larrea-Sebal A; Jarauta E; Lamiquiz-Moneo I; Calmarza P; Bea AM; Plana N; Pintó X; Martín C; Civeira F
    Atherosclerosis; 2022 May; 349():211-218. PubMed ID: 34456049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing the high-risk patient: therapeutic approaches in 2002.
    Schuster H;
    Atheroscler Suppl; 2003 Mar; 4(1):15-20. PubMed ID: 12714033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden.
    Rallidis LS; Kosmas N; Tsirebolos G; Rallidi M; Kiouri E; Kalpakos D
    J Clin Lipidol; 2019; 13(3):502-508. PubMed ID: 30956097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
    Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
    Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Heterozygous familial hypercholesterolemia].
    Özcan ÖU; Güleç S
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 2():10-8. PubMed ID: 25693359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol.
    Della Badia LA; Elshourbagy NA; Mousa SA
    Pharmacol Ther; 2016 Aug; 164():183-94. PubMed ID: 27133571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study).
    Pérez de Isla L; Alonso R; Mata N; Saltijeral A; Muñiz O; Rubio-Marin P; Diaz-Diaz JL; Fuentes F; de Andrés R; Zambón D; Galiana J; Piedecausa M; Aguado R; Mosquera D; Vidal JI; Ruiz E; Manjón L; Mauri M; Padró T; Miramontes JP; Mata P;
    Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):2004-10. PubMed ID: 27444203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maternally inherited hypercholesterolemia does not modify the cardiovascular phenotype in familial hypercholesterolemia.
    Marco-Benedí V; Laclaustra M; Bea AM; Suarez-Tembra M; Plana N; Pinto X; Brea A; Sanchez-Hernandez RM; Civeira F
    Atherosclerosis; 2021 Mar; 320():47-52. PubMed ID: 33529866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia.
    Langslet G; Breazna A; Drogari E
    J Clin Lipidol; 2016; 10(5):1153-1162.e3. PubMed ID: 27678432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Heterozygous familial hypercholesterolemia: the first challenge for anti-PCSK9 monoclonal antibodies].
    Zambon A
    G Ital Cardiol (Rome); 2016 Apr; 17(4 Suppl 1):22S-30. PubMed ID: 27312020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.